Occurrence of extended spectrum β-lactamases among isolates of enterobacteriaceae from urinary tract infections in southern Italy

Microbial Drug Resistance

Volumn 12, Issue 4, 2006, Pages 257-264

  Caccamo, Marisa ^a   Perilli, Mariagrazia ^b   Celenza, Giuseppe ^b   Bonfiglio, Giovanni ^a   Tempera, Gianna ^a   Amicosante, Gianfranco ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLA GENE; DNA SEQUENCE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; ITALY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ITALY; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE;

EID: 33846214038     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2006.12.257     Document Type: Article

References (35)

1. Bonnet, R. 2004. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1-14.
2. Bonnet, R., C. Dutour, J.L.M. Simpaio, C. Chanal, D. Sirot, R. Labia, C. De Champs, and J. Sirot. 2001. Novel cefotaximase (CTX-M-16) with increased catalytic efficient due to substitution Asp-240-Gly. Antimicrob. Agents Chemother. 45:2269-2275.
3. Bonnet, R., C. Recule, R. Baraduc, C. Chanal, D. Sirot, C. De Champs, and J. Sirot. 2003. Effect of D240G substitution in a novel ESBL CTX-M-27. J. Antimicrob. Chemother. 52:29-35.
4. Bradford, P.A. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol. Rev. 14:933-951.
5. Brigante, G., F. Luzzaro, M. Perilli, G. Lombardi, A. Colì, G.M. Rossolini, G. Amicosante, and A. Toniolo. 2005. Evolution of CTX-M-type β-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int. J. Antimicrob. Agents 25:157-162.
6. Bush, K., G.A. Jacoby, and A.A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
7. Cartelle, M., M. Tomas, F. Molina, R. Moure, R. Villanueva, and G. Bou. 2004. High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution. Antimicrob. Agents Chemother. 48:2308-2313.
8. Chomarat, M. 2000. Resistance of bacteria in urinary tract infections. Int. J. Antimicrob. Agents 16:483-487.
9. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. CLSI document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
10. De Champs, C., D. Sirot, C. Chanal, R. Bonnet, and J. Sirot. 2000. A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group. Antimicrob. Agents Chemother. 44:3177-3179.
11. Hujer, A.M., M.G.P. Page, M.S. Helfand, B. Yeiser, and R. Bonomo. 2002. Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV β-lactamases. J. Clinic. Microbiol. 40:1947-1957.
12. Jarlier, V., M.H. Nicolas-Chanoine, G. Fournier, and A. Philippon. 1988. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10:867-878.
13. Karaca, Y., N. Coplu, A. Gozalan, O. Oncul, B.E. Citil, and B. Esen. 2005. Co-trimoxazole and quinolone resistance in Escherichia coli isolated from urinary tract infections over the last 10 years. Int. J. Antimicrob. Agents 26:75-77.
14. Kim, J., Y.M. Lim, Y.S. Jeong, and S.Y. Seol. 2005. Occurrence of CTX-M-3, CTX-M-15, CTX-M-14 and CTX-M-9 Extended-spectrum β-lactamases in Enterobacteriaceae clinical isolates in Korea. Antimicrob. Agents Chemother. 49:1572-1575.
15. Kim, S., J. Kim, Y. Kang, Y. Park, and B. Lee. 2004. Occurrence of extended-spectrum beta-lactamases in members of the genus Shigella in the Republic of Korea. J. Clin. Microbiol. 42:5264-5269.
16. Livermore, D.M. 1995. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
17. Luzzaro, F., E. Mantegoli, M. Perilli, G. Lomabrdi, V. Orlandi, A. Orsatti, G. Amicosante, G.M. Rossolini, and A. Toniolo. 2001. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J. Clin. Microbiol. 39:1865-1870.
18. Martinez-Martinez, L., A. Pascual, M.C. Conejo, I. Garcia, P. Joyanes, A. Doménech-Sànchez, and V.J. Benedì. 2002. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of klebsiella pneumoniae and relationship to extended-spectrum β-lactamase production. Antimicrob. Agents Chemother. 46:3926-3932.
19. Nicolle, L.E. 2002. Urinary tract infection: traditional pharmacologic therapies. Am. J. Med. 113:358-448.
20. Nordman, P., E. Ronco, T. Naas, C. Duport, Y. Michel-Briand, and R. Labia. 1993. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:962-969.
21. Pagani, L., E. Mantengoli, R. Migliavacca, E. Nucleo, S. Pollini, M. Spalla, R. Daturi, E. Romero, and G.M. Rossolini. 2004. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producine the PER-1 extended-spectrum β-lactamase in Northern Italy. J. Clin. Microbiol. 42:2523-2529.
22. Pagani, L., R. Migliavacca, L. Pallecchi, C. Matti, E. Giacobone, G. Amicosante, E. Romero, and G.M. Rossolini. 2002. Emerging extended-spectrum β-lactamases in Proteus mirabilis. J. Clin. Microbiol. 40:1549-1552.
23. Pallecchi L., M. Malossi, A. Mantella, E. Gotuzzo, C. Trigoso, A. Bartoloni, F. Paradisi, G. Kronvall, and G.M. Rossolini. 2004. Detection of CTX-M-type β-lactamase genes in fecal Escherichia coli isolates from healthy children in Bolivia and in Peru. Antimicrob. Agents Chemother. 48:4556-4561.
24. Paterson, D.L., and R.A. Bonomo. 2005. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
25. Perilli, M., C. Mugnaioli, F. Luzzaro, M. Fiore, S. Stefani, G.M. Rossolini, and G. Amicosante. 2005. Novel TEM-type extended-spectrum β-lactamase, TEM-134, in a Citrobacter koseri clinical isolate. Antimicrob. Agents Chemother. 49:1564-1566.
26. Perilli, M., E. Dell'Amico, B. Segatore, M.R. De Massis, C. Bianchi, F. Luzzaro, G.M. Rossolini, A. Toniolo, G. Nicoletti, and G. Amicosante. 2002. Molecular characterization of extended spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J. Clin. Microbiol. 40:611-614.
27. Pitout, J.D., P. Nordmann, K.B. Laupland, and L. Poirel. 2005. Emergence of Enterobacteriaceae producing extended-spectrum (ES/3Ls) in the community. J. Antimicrob. Chemother. 56:52-59.
28. Poirel, L., M. Gniadkowski, and P. Nordmann. 2002. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and its structurally related β-lactamase CTX-M-3. J. Antimicrob. Chemother. 50:1031-1034.
29. Quinteros, M., M. Radice, N. Gardella, M.M. Rodriguez, N. Costa, D. Korbenfeld, E. Couto, and G. Gutkind. 2003. Extended-spectrum beta-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob. Agents Chemother. 47:2864-2867.
30. Sefton, A.M. 2000. The impact of resistance on the management of urinary tract infections. Int. J. Antimicrob. Agents 16:489-491.
31. Spanu, T., F. Luzzaro, M. Perilli, G. Amicosante, A. Toniolo, and G. Fadda. 2002. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob. Agents Chemother. 46:196-202.
32. Szabo, D., R.A. Bonomo, F. Silveira, A.W. Pasculle, C. Baxter, P.K. Linden, A.M. Hujer, K.M. Hujer, K. Deeley, and D. Paterson. 2005. SHV-type extended-spectrum β-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae. J. Clin. Microbiol. 43:5058-5064.
33. Tempera, G., M. Mirabile, A. Mangiafico, M. Caccamo, and G. Bonfiglio. 2004. Fosfomycin tromethamine in uncomplicated urinary tract infections: an epidemiological survey. J. Chemother. 16:216-217.
34. Villart, H.E., F. Danel, and D.M. Livermore. 1997. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other β-lactams. J. Antimicrob. Chemother. 40:365-370.
35. Bush, K., and G.A. Jacoby. 2005. www.lahey.org/studies/webt.htm Last accessed January 20, 2006.